From Medscape Oncology

Coverage from the

World Conference on Lung Cancer (WCLC) 2021

September 08 - 14, 2021; Virtual/Online

September 08 - 14, 2021 Virtual/Online

Conference News

WCLC 2021 Most Community-Based Oncologists Skip Biomarker Testing
Medscape Medical News, September 23, 2021
WCLC 2021 Improved Survival in Patients With NSCLC and Brain Metastases
Medscape Medical News, September 17, 2021
WCLC 2021 'Urgent' Need to Understand Immunotherapy De-escalation in NSCLC
Medscape Medical News, September 17, 2021
WCLC 2021 'Concerning' Low Rates of Durvalumab Maintenance Therapy in NSCLC in US
Reuters Health Information, September 16, 2021
WCLC 2021 Tackling Grief, Loss in Patients With Advanced Lung Cancer
Medscape Medical News, September 16, 2021
WCLC 2021 Unequal Resource Distribution Underlies Lung Cancer Disparities
Medscape Medical News, September 13, 2021

WCLC 2021 Pandemic Strategies to Boost Trial Enrollment Should Stay
Medscape Medical News, September 13, 2021
WCLC 2021 Air Pollution ― Second Leading Cause of Lung Cancer
Medscape Medical News, September 13, 2021
WCLC 2021 Which Patients Benefit Most From Adjuvant Atezolizumab in NSCLC?
Medscape Medical News, September 11, 2021
WCLC 2021 ATLANTIS Results: Lurbinectedin Plus Doxorubicin in SCLC
Medscape Medical News, September 10, 2021
WCLC 2021 POSEIDON: Two ICIs Plus Chemo Up Survival in mNSCLC
Medscape Medical News, September 10, 2021

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

Small Cell Lung Cancer Highlights From IASLC 2021
Ramaswamy Govindan, MD

Popular News from WCLC 2020

'Unprecedented' Long-term Survival After IO in Pretreated NSCLC For patients with non–small cell lung cancer (NSCLC) who experience disease progression with chemotherapy, immunotherapy (IO) offers an "unprecedented" chance of long-term survival, says an expert.
Medscape Medical News, Feb 09, 2021
Screening for Lung Cancer in Never-Smokers 'Feasible' Screening for lung cancer with low-dose computed tomography (LDCT) has so far been targeted to smokers, but screening of never-smokers is "feasible," say researchers.
Medscape Medical News, Feb 02, 2021
Nivolumab Improves Survival in Relapsed Mesothelioma In the first placebo-controlled phase 3 trial in relapsed mesothelioma, immunotherapy with nivolumab showed a significant improvement in survival.
Medscape Medical News, Feb 01, 2021

Previous Coverage